Patents by Inventor Phillip Kennedy
Phillip Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076402Abstract: Methods for using anti-LIV1 antibodies, including drug conjugated anti-LIV1 antibodies, to inhibit proliferation of a LIV-1-expressing cell, as well as for the treatment of one or more diseases or disorders associated with LIV-1-expressing cells (e.g., a LIV-1-associated breast cancer), are provided.Type: ApplicationFiled: March 7, 2023Publication date: March 7, 2024Inventors: Dana KENNEDY, Ana KOSTIC, Elizabeth CORWIN, Jonathan DRACHMAN, Peter HAUGHNEY, Baiteng ZHAO, Phillip GARFIN, Maria Corinna PALANCA-WESSELS, Oyewale O. ABIDOYE
-
Publication number: 20240041792Abstract: The present invention relates to a topical composition comprising a cannabinoid, extracellular matrix component or extracellular matrix fragment, and a pharmaceutically acceptable carrier, excipient, diluent, reagent, or combinations thereof, and use thereof in the treatment skin disorders, muscle pain, and arthritic pain.Type: ApplicationFiled: July 26, 2023Publication date: February 8, 2024Applicant: TRUETIVA, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20230277477Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.Type: ApplicationFiled: May 15, 2023Publication date: September 7, 2023Applicant: TRUETIVA, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20230270690Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.Type: ApplicationFiled: May 9, 2023Publication date: August 31, 2023Applicant: TRUETIVA, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20220257482Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, or cannabidiol analog for lightening or whitening skin, and methods for lightening skin tone or whitening skin by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin.Type: ApplicationFiled: April 25, 2022Publication date: August 18, 2022Inventor: J. Phillip KENNEDY
-
Patent number: 11337905Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, or cannabidiol analog for lightening or whitening skin, and methods for lightening skin tone or whitening skin by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin.Type: GrantFiled: January 14, 2019Date of Patent: May 24, 2022Assignee: Truetiva, Inc.Inventor: J. Phillip Kennedy
-
Patent number: 11318137Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.Type: GrantFiled: May 17, 2017Date of Patent: May 3, 2022Assignee: Vanderbilt UniversityInventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
-
Publication number: 20220117990Abstract: Compounds capable of binding to and inhibiting the activity of RAS protein are described herein along with compositions and methods useful for treating RAS protein related diseases such as, for example, cancer.Type: ApplicationFiled: September 29, 2021Publication date: April 21, 2022Applicant: Truetiva, Inc.Inventor: J. Phillip Kennedy
-
Publication number: 20210393546Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating viral infections, and methods for treating viral infections by topically or orally administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment.Type: ApplicationFiled: June 19, 2020Publication date: December 23, 2021Applicant: SHAMAN NATURALS, LLCInventors: Maria CRISLER, Emma DiPONIO, J. Phillip KENNEDY
-
Patent number: 11020334Abstract: This application relates to compounds prepared from cosmetically acceptable ingredients, methods of preparation thereof, and use thereof. Compounds are of formula (I) U—C—B, or salts thereof, wherein U, C and B are moieties of cosmetically acceptable ingredients U?, C? and B?. In living tissues, the compounds can release at least one of U?, C? and B?. The bond between C and U and/or between C and B is labile in living tissues. In particular, the compounds comprise moieties derived from salicylic acid, retinol and retinoic acid or nicotinic acid.Type: GrantFiled: February 17, 2018Date of Patent: June 1, 2021Assignee: Illustris Pharmaceuticals, Inc.Inventors: J. Phillip Kennedy, Jacob M. Waugh
-
Publication number: 20210015762Abstract: Embodiments of the invention are directed to compositions containing cannabinoids and bioenhancers for treating obesity, eating disorders, metabolic disorders, and other body weight related diseases and disorders, and methods for treating obesity, eating disorders, metabolic disorders, and other body weight related diseases and disorders by administering compositions containing cannabinoid and a bioenhancer.Type: ApplicationFiled: July 16, 2020Publication date: January 21, 2021Applicant: Truetiva, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20200253974Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.Type: ApplicationFiled: May 17, 2017Publication date: August 13, 2020Inventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
-
Publication number: 20200054538Abstract: This application relates to compounds prepared from cosmetically acceptable ingredients, methods of preparation thereof, and use thereof. Compounds are of formula (I) U—C—B, or salts thereof, wherein U, C and B are moieties of cosmetically acceptable ingredients U?, C? and B?. In living tissues, the compounds can release at least one of U?, C? and B?. The bond between C and U and/or between C and B is labile in living tissues. In particular, the compounds comprise moieties derived from salicylic acid, retinol and retinoic acid or nicotinic acid.Type: ApplicationFiled: February 17, 2018Publication date: February 20, 2020Inventors: J. Phillip Kennedy, Jacob M. Waugh
-
Publication number: 20200009077Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.Type: ApplicationFiled: July 3, 2019Publication date: January 9, 2020Applicant: TRUETIVA, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20200009078Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.Type: ApplicationFiled: July 3, 2019Publication date: January 9, 2020Applicant: TRUETIVA, Inc.Inventor: J. Phillip KENNEDY
-
Publication number: 20190216695Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, or cannabidiol analog for lightening or whitening skin, and methods for lightening skin tone or whitening skin by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin.Type: ApplicationFiled: January 14, 2019Publication date: July 18, 2019Inventor: J. Phillip KENNEDY
-
Patent number: 9430617Abstract: Systems and methods for content selection and processing in an information system are described herein. In one example, a content suggestion engine operates to select, suggest, or recommend content to human users. The selection of content may be suited to a goal or set of goals set by a human user (for example, content recommendations used to assist the human user with achieving a personal health goal). The content suggestion engine may evaluate information to help determine the appropriateness of the content suggestions, considering factors such as a psychological profile, medical conditions, lifestyle, demographics, and goals. The content may be further filtered and weighted to select a subset of content and suggested actions most relevant to the human user.Type: GrantFiled: May 15, 2015Date of Patent: August 30, 2016Assignee: Wellclub, LLCInventors: Thomas Edwin Brust, Phillip Kennedy, Jamal Khan, Jay W. Johnson, Tom Waddell
-
Publication number: 20160030452Abstract: This invention relates generally to minocycline derivatives, and to compositions, including pharmaceutical compositions, containing such minocycline derivatives. The invention also relates to methods of synthesizing minocycline derivatives and to methods for using such minocycline derivatives as anti-bacterial agents for treating or preventing infections.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Inventors: JACOB M. WAUGH, JACK PHILLIP KENNEDY
-
Publication number: 20100035929Abstract: Disclosed are dispyrin analogue compounds useful as H3 receptor activity modulators, methods of making same, pharmaceutical compositions comprising same, and methods of treating neurological and psychiatric disorders associated with histamine H3 receptor activity using same. In one aspect, the disclosed analogues can have a structure represented by a formula: This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 8, 2009Publication date: February 11, 2010Inventors: Craig W. Lindsley, P. Jeffrey Conn, J. Phillip Kennedy, John T. Brogan